In the most recent research criteria from the International Working Group for the diagnosis of AD published in 2014 [36], the diagnosis of prodromal AD requires both the presence of cognitive symptoms and AD signature biomarker profile (increased amyloid positron emission tomography [PET] deposition or the combination of lowered CSF amyloid-β1–42 and elevated CSF tau). This evidence concerns the gene MAPT and Alzheimer disease.